2020
DOI: 10.1016/s2352-4642(19)30336-0
|View full text |Cite
|
Sign up to set email alerts
|

Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
65
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 84 publications
(66 citation statements)
references
References 47 publications
1
65
0
Order By: Relevance
“…Even among sites currently using STS, criteria for its use vary across tumor types, with greatest consensus surrounding use only for the treatment of localized hepatoblastoma. This pattern of use is consistent with a recently published clinical practice guideline for STS 22 . This new guideline may alleviate concerns at those sites that identified the need for consensus input into use of STS.…”
Section: Discussionsupporting
confidence: 81%
“…Even among sites currently using STS, criteria for its use vary across tumor types, with greatest consensus surrounding use only for the treatment of localized hepatoblastoma. This pattern of use is consistent with a recently published clinical practice guideline for STS 22 . This new guideline may alleviate concerns at those sites that identified the need for consensus input into use of STS.…”
Section: Discussionsupporting
confidence: 81%
“…As it is unlikely cisplatin will be replaced by other agents to treat childhood cancer any time soon, monitoring its impact on a child's development and education, increasing awareness of its effects and support for families, and finding ways to prevent ototoxicity are the key medical needs for the foreseeable future. The results of recent oto-protection clinical trials testing agents to mitigate cisplatin hearing loss have recently been assessed and a clinical guideline published [14,15].…”
Section: Cisplatinmentioning
confidence: 99%
“…In 2019 a clinical guideline paper was written by a multidisciplinary team led by Lillian Sung and David Freyer [15]. The conclusion of this paper was that to date the most promising otoprotectant is STS, see Table 2 taken from this paper.…”
Section: Clinical Trials Of Otoprotectants In Childrenmentioning
confidence: 99%
“…However, in patients with disseminated disease, those who received STS showed lower overall survival than patients in the control group 3 . The expert panel made a strong recommendation for STS administration in patients with non‐metastatic hepatoblastoma, a weak recommendation for STS administration in patients with other non‐metastatic cancers, and a weak recommendation against its routine use in metastatic cancers 4 . We report the case of a patient with medulloblastoma who was monitored by periodic serial evaluations for ototoxicity and in which the progression of CIHL was prevented by STS.…”
Section: Figmentioning
confidence: 99%